Hence, the downregulation of the METTL3-YTHDF1-FOXO3 axis crucially contributes to sorafenib resistance, and targeting of YTHDF1 represents a novel therapeutic approach to enhance sorafenib response in HCC [41]. Here, YTHDF1 is linked to hepatocellular carcinoma.